Document is current
Any future updates will be listed below
-
Authors
Wajih, Nadeem
Erali, Richard A.
Forsythe, Steven D.
Schaaf, Cecilia R.
Shen, Perry
Levine, Edward A.
Soker, Shay
Morris, David L.
Votanopoulos, Konstantinos I.
-
Funding
Funding for this research was provided by:
Appendix Cancer Pseudomyxoma Peritonei Research Foundation
Foundation for the National Institutes of Health (CA249087, CA258692)
Mucpharm Pty Ltd
Wake Forest University
- License Information
-
More Information
Article History
Received: 16 February 2024
Accepted: 9 April 2024
First Online: 4 May 2024
Disclosure
: Dr. David Morris is CEO and cofounder of Mucpharm Pty Ltd and provided bromelain materials and additional financial support for this work. Dr. Konstantinos Votanopoulos declares Organoid released patents. This research stems from the Wake Forest Organoids Research Center and was supported by the Wake Forest Institute for Regenerative Medicine, the Tumor Tissue and Pathology Shared Resource, Mucpharm Pty Ltd, and the Appendix Cancer Pseudomyxoma Peritonei Foundation (ACPMP). The other authors declare no conflicts of interest.
